Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 1;140(5):861-868.
doi: 10.1097/AOG.0000000000004959. Epub 2022 Oct 5.

Trends in and Outcomes of Deliveries Complicated by Cystic Fibrosis

Christina N Schmidt  1 , Alexander M Friedman, Emily A DiMango, Alice H Linder, Nasim C Sobhani, Mary E D'Alton, Timothy Wen
Affiliations

Trends in and Outcomes of Deliveries Complicated by Cystic Fibrosis

Christina N Schmidt et al. Obstet Gynecol. .

Abstract

Objective: To characterize current trends and outcomes in pregnancies complicated by cystic fibrosis (CF) that resulted in delivery.

Methods: This repeated cross-sectional study used the U.S. National Inpatient Sample to identify delivery hospitalizations of patients with CF between 2000 and 2019. Trends in delivery hospitalizations of patients with CF were assessed using joinpoint regression to determine the average annual percent change (AAPC). The risk of adverse maternal and obstetric outcomes was compared between patients with and without CF using adjusted logistic regression models accounting for demographic, clinical, and hospital characteristics, with adjusted odds ratios (aORs) with 95% CIs as measures of association. The proportion of patients with CF and other chronic conditions such as pregestational diabetes was analyzed over time.

Results: From 2000 to 2019, the prevalence of CF at delivery increased from 2.1 to 10.4 per 100,000 deliveries (AAPC 6.7%, 95% CI 5.7-8.2%). The proportion of patients with CF and other chronic conditions increased from 18.0% to 37.3% (AAPC 3.1%, 95% CI 1.0-5.3%). Patients with CF were more likely to experience severe maternal morbidity (aOR 2.61, 95% CI 1.71-3.97), respiratory complications (aOR 17.45, 95% CI 11.85-25.68), venous thromboembolism (aOR 3.59, 95% CI 1.33-9.69), preterm delivery (aOR 2.15, 95% CI 1.79-2.59), abruption and antepartum hemorrhage (aOR 1.63, 95% CI 1.10-2.41), and gestational diabetes (aOR 2.47, 95% CI 2.47-3.70).

Conclusion: Although still infrequent (approximately 1 in 10,000), deliveries complicated by CF increased approximately fivefold over the study period. The proportion of patients with CF and other chronic conditions is increasing. Patients with CF are at increased risk for a broad range of adverse outcomes.

PubMed Disclaimer

Conflict of interest statement

Financial Disclosure : Mary D'Alton had a senior leadership role in ACOG II's Safe Motherhood Initiative, which received unrestricted funding from Merck for Mothers. Timothy Wen serves as a consultant on the medical advisory board for Delfina Care Inc. The other authors did not report any potential conflicts of interest.

References

    1. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation patient registry: 2020 annual data report. CFF; 2021.
    1. Wine JJ. The genesis of cystic fibrosis lung disease. J Clin Invest 1999;103:309–12. doi: 10.1172/JCI6222 - DOI
    1. Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet 2021;397:2195–211. doi: 10.1016/S0140-6736(20)32542-3 - DOI
    1. National Heart, Lung and Blood Institute. Cystic fibrosis. Accessed February 23, 2022. https://www.nhlbi.nih.gov/health-topics/cystic-fibrosis
    1. Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al . Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 2019;394:1940–8. doi: 10.1016/S0140-6736(19)32597-8 - DOI